Thermo Fisher's abandoned QIAGEN bid (2020)
Thermo Fisher Scientific agreed to buy QIAGEN for about $11.5 billion, after QIAGEN's CEO left in late 2019. The deal came as QIAGEN's share price had fallen to multi-year lows.
Thermo Fisher abandoned the takeover after failing to secure enough shareholder support.
QIAGEN stayed public, then saw demand surge for its COVID-19 testing products, which led some investors to view the 2020 offer as too low.
The failed 2020 bid shows shareholder sentiment can sink a deal for QIAGEN, a risk EQT's current offer must overcome.
